2017 Cell and Gene Therapy Heatmap - Europe The Road To Commercialisation
Over the last 12 months, the cell and gene therapy manufacturing sphere has matured vastly with more companies advancing to commercial products, especially with allogenic therapies. Now that the theory behind the therapy is catching up with the technology, the two can come together to progress towards producing commercial products. Last year Pharma IQ examined the UK with our Cell and Gene Manufacturing hotspot map. This year we broaden our focus to scan the cell and gene manufacturing activity that is occurring across Europe regarding the road to commercialised therapies.
If you prefer to receive this via email contact Stephen.Aponte@iqpc.com.
Please note: That all fields marked with an asterisk (*) are required.